Intravenous Exenatide in Coronary Intensive Care Unit (ICU) Patients

• Status: Completed
• Trial end date: 2012-08-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine the efficacy of intravenous Exenatide therapy in hyperglycemic patients admitted to the coronary intensive care unit.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Saint Luke's Health System
• Collaborator: Amylin Pharmaceuticals, LLC.
• Treatments: Exenatide

Criteria

Inclusion Criteria:

• Admission to coronary ICU

• Admission blood glucose 140-299 mg/dL

• Primary cardiovascular diagnosis by attending physician

• Under primary care of cardiology service

• Age > 18 years old

• Ventilator independent

• Able to provide informed consent

Exclusion Criteria:

• Admission blood glucose < 140 or > 300 mg/dL

• Ventilator dependent

• Unconscious sedation

• Type 1 diabetes

• Known pregnancy

• Admitted to coronary ICU for right heart cath to measure hemodynamics prior to transplant

• Post transplant procedure

• Currently enrolled in another clinical trial

• Unable to provide informed consent

• Creatinine clearance < 30 mL/min

• On insulin treatment except for monotherapy with long-acting basal insulin (e.g., insulin glargine [Lantus®] or detemir [Levemir®])

• Gastroparesis